Dahlak Daniel Solomon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dahlak Daniel Solomon has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Chih-Yang Wang
PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
3 shared publications - Hui-Pu Liu
Department of General Surgery, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan
2 shared publications Sachin Kumar
Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Solan, India
2 shared publications- Chan-Chuan Liu
National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
1 shared publication - Cheng-Lin Wu
Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
1 shared publication - Chia-Hung Chien
College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
1 shared publication
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in Cell Communication and Signaling
Tumor-derived RPS19 engages C5AR1+ inflammatory macrophages to drive astrocyte reprogramming and glioblastoma progression
- 8 August 2026
- Published by Springer Nature in Cell Communication and Signaling
Open AccessTumor-derived RPS19 engages C5AR1+ inflammatory macrophages to drive astrocyte reprogramming and glioblastoma progression
- Open Access
- 11 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 455
Comprehensive In Silico Investigation of L-Glutamine Transporters and Metabolism in Glioblastoma
Background/Objectives: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains associated with poor prognosis despite multimodal therapy. Metabolic reprogramming, particularly increased dependence on glutamine, supports GBM bioenergetic, biosynthetic, and redox demands. This study aimed to systematically identify glutamine-associated metabolic regulators with prognostic relevance and biological plausibility in GBM. Methods: Transcriptomic data from TCGA and GTEx were analyzed using GEPIA2, with survival validation performed using the CGGA. Functional pathway enrichment, protein expression assessment, protein–protein interaction network analysis, tumor microenvironment evaluation, epigenetic profiling, and single-cell RNA sequencing validation were integrated to contextualize candidate genes. Pharmacogenomic correlation analysis and structure-based molecular docking were applied as supportive validation layers. Results: Ceruloplasmin (CP), Solute Carrier Family 25 Member 13 (SLC25A13), and Solute Carrier Family 38 Member 2 (SLC38A2) were selectively dysregulated and associated with poor clinical outcomes in GBM. CP was linked to redox regulation and stress-adaptive survival programs, SLC25A13 to mitochondrial metabolite exchange and glutamine-coupled nucleotide biosynthesis, and SLC38A2 to glutamine uptake, nutrient sensing, and mTORC1-MYC-associated growth signaling. Conclusions: CP, SLC25A13, and SLC38A2 emerge as clinically relevant glutamine-associated metabolic regulators in GBM, linking redox regulation, mitochondrial metabolite exchange, and glutamine-driven growth signaling. These findings highlight transport- and exchange-centered metabolic nodes as potential biomarkers and candidates for future metabolic targeting in GBM.
- 11 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 455
Open AccessComprehensive In Silico Investigation of L-Glutamine Transporters and Metabolism in Glioblastoma
Background/Objectives: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains associated with poor prognosis despite multimodal therapy. Metabolic reprogramming, particularly increased dependence on glutamine, supports GBM bioenergetic, biosynthetic, and redox demands. This study aimed to systematically identify glutamine-associated metabolic regulators with prognostic relevance and biological plausibility in GBM. Methods: Transcriptomic data from TCGA and GTEx were analyzed using GEPIA2, with survival validation performed using the CGGA. Functional pathway enrichment, protein expression assessment, protein–protein interaction network analysis, tumor microenvironment evaluation, epigenetic profiling, and single-cell RNA sequencing validation were integrated to contextualize candidate genes. Pharmacogenomic correlation analysis and structure-based molecular docking were applied as supportive validation layers. Results: Ceruloplasmin (CP), Solute Carrier Family 25 Member 13 (SLC25A13), and Solute Carrier Family 38 Member 2 (SLC38A2) were selectively dysregulated and associated with poor clinical outcomes in GBM. CP was linked to redox regulation and stress-adaptive survival programs, SLC25A13 to mitochondrial metabolite exchange and glutamine-coupled nucleotide biosynthesis, and SLC38A2 to glutamine uptake, nutrient sensing, and mTORC1-MYC-associated growth signaling. Conclusions: CP, SLC25A13, and SLC38A2 emerge as clinically relevant glutamine-associated metabolic regulators in GBM, linking redox regulation, mitochondrial metabolite exchange, and glutamine-driven growth signaling. These findings highlight transport- and exchange-centered metabolic nodes as potential biomarkers and candidates for future metabolic targeting in GBM.